Pfizer has approached U.S. cancer drug maker Medivation to express interest in an acquisition, raising the possibility of a bid. » Read More
CNBC's Meg Tirrell reports on a new tactic by some in Congress to question the price of high-cost drugs.
A study found that Theranos produces more irregular results than conventional laboratories, The New York Times reports.
CNBC's Meg Tirrell reports on Alder Biopharmaceuticals' chronic migraine drug trial and how other pharma companies are developing new treatments and therapies, as well as the latest on Valeant CEO Mike Pearson's subpoena.
CNBC's Meg Tirrell reports that Valeant CEO Mike Pearson has received a subpoena to testify to a Senate panel.
A federal jury has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.
U.S. legislators have asked William Ackman's hedge fund for information on Valeant, according to a person familiar with the matter.
Let the free market decide the availability, cost and need for any drug or treatment, says Jake Novak.
Merck's claims upheld in a California court, but Gilead told CNBC that it will appeal the case.
South Korea reported its first confirmed case of the Zika virus on Tuesday, its center for disease control said.
Valeant announces that CEO Mike Pearson is leaving and that former CFO Howard Schiller refused to quit the board to make room for Bill Ackman.
Chinese authorities are hunting 300 people suspected of illegally selling spoiled vaccines to medical centers across the country, state media said.
Intrexon CEO tells CNBC's Power Lunch that he would not go to Brazil with Zika virus outbreak.
CNBC's Meg Tirrell gives a recap on Valeant Pharma's troubles this week including their plunging share price and looming debt timeline.
Howard Dorfman testified he was fired weeks after telling CEO Martin Shkreli the increase "was not justified." USA Today reports.
Biotechs are still sinking, so when should you buy these stocks? The FMHR traders and Stephanie Link, TIAA Equities portfolio manager, share their strategy.
Les Funtleyder, Asset Management Portfolio Manager at ESquared, gives his take on Valeant Pharmaceuticals and the pharma and health care sectors.
CNBC's Meg Tirrell looks at the next steps for beleaguered Valeant Pharma, including their looming debt deadlines and possible divestitures.
After Valeant took a bite out of Bill Ackman's hedge fund, the billionaire described his firm's standing to CNBC's Scott Wapner.
GlaxoSmithKline said its CEO Andrew Witty would retire in 12 months, prompting Britain's biggest drugmaker to start a formal search for his successor.
Creditors of Valeant Pharmaceuticals are beginning to demand new terms that could further pressure the drugmaker's business model, sources said.
Get the best of CNBC in your inbox